Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$180.96 USD

180.96
830,357

+2.38 (1.33%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $180.89 -0.07 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Charles River (CRL) to Report Q4 Earnings: What's in Store?

The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.

Charles River (CRL) Launches Animal-Free Endotoxin Test

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

Charles River's (CRL) New Launch to Boost Gene Therapy Programs

Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.

Charles River's (CRL) Memphis Site Achieves Crucial Approval

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.

Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe

At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal

Charles River (CRL) and GC4K announce a gene therapy manufacturing collaboration.

Charles River (CRL) Widens CliniPrime GMP Suite With New Launch

Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.

Charles River (CRL) to Advance AI Drug Discovery With New Pact

Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

Charles River's (CRL) Q3 Earnings Beat, Margins Decline

Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.

Charles River (CRL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Unlocking Q3 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Charles River (CRL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.

Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to Decline

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) to Report Q3 Earnings: What's in Store?

Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.

Why Charles River (CRL) Could Beat Earnings Estimates Again

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Charles River (CRL) Offers Access to Preclinical Cancer Research

Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.

Charles River (CRL) Launches LVV-based Gene Therapy Platform

Charles River's (CRL) LVV platform provides medicinal developers with an efficient, dependable route to the clinic and the market.

Charles River (CRL) Opens a RightSource Lab in Stevenage

Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.

Charles River (CRL) Announces Partnership With Related Sciences

Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica.

Charles River (CRL) Down 6.1% Since Last Earnings Report: Can It Rebound?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) on the RMS segment's continued growth and upbeat guidance.